| 摘要 |
<p>The present invention relates to a pharmaceutical composition comprising lisinopril and dibasic calcium phosphate dihydrate (DCPD), produced by a process comprising mixing lisinopril and DCPD with a specific surface area of less than 1.5 m2g-1. The use of large particle sized DCPD in a lisinopril formulation/composition has the effect of reducing the amount of the lisinopril degradation product DKP that is formed, thereby increasing the shelf-life of tablets formulated with the larger sized DCPD, particularly those with low doses of lisinopril.</p> |
